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Abstract
‘Hard-to-heal’ wounds are those which fail to heal with standard therapy in an orderly
and timely manner and may warrant the use of advanced treatments such as non-contact
low-frequency ultrasound (NLFU) therapy. This evaluator-blinded, single-site, ran-
domised controlled trial, compared NLFU in addition to UK standard of care [SOC:
(NLFU+ SOC)] three times a week, with SOC alone at least once a week. Patients with
chronic venous leg ulcers were eligible to participate. All 36 randomised patients com-
pleted treatment (17 NLFU+ SOC, 19 SOC), and baseline demographics were com-
parable between groups. NLFU+SOC patients showed a −47% (SD: 38%) change in
wound area; SOC, −39% (38%) change; and difference, −7⋅4% [95% confidence inter-
vals (CIs) −33⋅4–18⋅6; P= 0⋅565]. The median number of infections per patient was
two in both arms of the study and change in quality of life (QoL) scores was not signif-
icant (P= 0⋅490). NLFU+ SOC patients reported a substantial mean (SD) reduction in
pain score of−14⋅4 (14⋅9) points, SOC patients’ pain scores reduced by−5⋅3 (14⋅8); the
difference was −9⋅1 (P= 0⋅078). Results demonstrated the importance of high-quality
wound care. Outcome measures favoured NLFU+ SOC over SOC, but the differences
were not statistically significant. A larger sample size and longer follow-up may reveal
NLFU-related improvements not identified in this study.
Introduction
Vascular ulcers (e.g. venous and arterial ulcers), diabetic
ulcers and pressure ulcers are classified as chronic wounds.
The scale of the problem of these wounds is huge and well
documented. Chronic wounds display characteristics such as
a prolonged inflammatory phase, persistent infections, forma-
tion of microbial biofilms and ineffective dermal/epidermal
cell response, which differentiate them from acute wounds
(1). However, if appropriate ‘standard of care’ (SOC) (2) is
initiated in a timely manner such chronic wounds can often
follow a normal healing trajectory. Troxler et al. introduces the
term ‘hard-to-heal’ which better explains a wound which fails
to heal with standard therapy in an orderly and timely manner
(3). Decades of research has led to a greater understanding of
the complex pathophysiology of chronic wounds, raising many
further questions in the process (4).
Chronic leg ulceration prevalence in the UK is estimated
to be 1%, with between 0⋅12% and 0⋅32% of the population
having an open ulcer (5). Venous leg ulcers (VLUs) become
more common with age, and many patients suffer from the
Key Messages
• hard-to-heal venous leg ulcers which do not respond to
standard of care (SOC) may require advanced therapies
such as non-contact low-frequency ultrasound (NLFU)
shown in previous studies to improve healing in chronic
wounds
• in their medical technologies guidance (MTG5), the
National Institute for Health and Care Excellence recom-
mended further research on NLFU
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• this open-label, assessor-blinded, randomised controlled
trial of 36 patients with chronic venous leg ulcers com-
pared the effect of a NLFU regime (three times a week)
with standard UK practice (at least once a week) on the
change in wound area after 8weeks of treatment, follow-
ing a 4-week run-in period
• substantial improvements were seen in both arms across
several outcome measures as a result of the application
of high-quality SOC which may mask any effect of the
technology
• improvements in wound area and pain in the NLFU treat-
ment groupwere not significant comparedwith that of the
control group; larger than estimated standard deviation in
the primary outcome meant that this study had reduced
statistical power
condition for a number of years (6). Patients with VLUs have
a substantially poorer quality of life (QoL) which is often
because of the pain, odour, recurrent wound infection and
reduced mobility associated with chronic leg ulceration (7).
The cost for treating unhealed venous ulceration in 2005/2006
to the NHS was at least £168million/year (8). Tennvall and
Hjelmgen (2005) (9) showed that the average total cost per
patient for treating a VLU for 52weeks in the UK ranged from
€1121 to 2142 depending on size and duration of the wound.
When a patient fails to respond to standard care treatments, to
reduce the long-term impact on the patients along with the huge
resources and costs incurred, advanced treatments may be con-
sidered. Advanced treatments, for example cell-based therapies
or non-contact low-frequency ultrasound (NLFU) therapy, have
been shown in small-scale studies to initiate healing which
more traditional dressings have failed to do (10–12).
MIST Therapy System (Celleration Inc., Eden Prairie, MN)
is a low-intensity (0⋅1–0⋅8W/cm2), NLFU device designed to
promote the healing of chronic wounds. The device delivers
continuous ultrasound energy (40-kHz frequency) through a
fine saline mist to the wound bed (13). It is claimed that sound
waves stimulate the cells within and below the wound bed to
promote wound healing through downregulation of inflamma-
tion, a reduction in the number of bacteria and an increase in
blood flow (14).
In 2011, the National Institute for Health and Care Excel-
lence (NICE, formerlyNational Institute for Health andClinical
Excellence) issued medical technologies guidance (MTG5)
(15) which stated that NLFU shows “potential to enhance
the healing of chronic, ‘hard-to-heal’, complex wounds, com-
pared with standard methods of wound management”. The
NICE committee noted that the quality of the evidence was
limited by small patient numbers and lack of appropriate
comparison groups. NICE’s published guidance recom-
mended comparative research in the UK to reduce uncertainty
about the outcomes of patients with chronic wounds treated
with NLFU therapy compared with those given only with
standard care.
At the time of this study, randomised controlled trials had
been carried out in patients with ischaemic limbs (16) and
patients with diabetic foot ulcers (10) treated using NLFU
therapy; since then a study on patients with VLUs has been
published (17) and a pilot study (18). These randomised
controlled trials (10,16,17) and several observational studies
(mostly retrospective; 12, 19–23) have reported that treatment
with NLFU improves wound healing. Kavros reported that sig-
nificantly more patients with ischaemic wounds treated with
NLFU achieved 50% wound closure at 12weeks compared
with those of SOC alone (63% versus 29%; P< 0⋅001). Ennis
et al. reported no significant difference in the number of dia-
betic foot ulcers healed after 12weeks of NLFU or SOC (26%
versus 22%; P= 0⋅69) by intention to treat analysis; but a
significant difference (40⋅7% versus 14⋅3%; P= 0⋅0366) from
‘per-protocol’ analysis. Extrapolating the results from Ennis
et al. (10,24) into a US-based cost model revealed savings of
19⋅5% from NLFU compared with SOC (25). Olyaie et al. (17)
found a statistically significant difference (P= 0⋅04) in VLU
sizes after 4months of treatment across three groups (standard
compression therapy, NLFU and high-frequency ultrasound);
although these patients were young (mean age of 39) and may
not have been ‘hard-to-heal’ (>4-week duration). Methodolog-
ical limitations, reporting issues and aetiological heterogeneity
of the study wounds have made results from previous clinical
trials difficult to interpret.
Our study is an integral part of NICE’s medical technologies
evaluation activities – to facilitate the development of further
evidence stemming from recommendations in published guid-
ance. Coupled with the fact that there is limited high-quality
evidence on patients with VLUs treated with NLFU, this study
has been designed to answer a specific research question posed
by NICE:what is the utility of NLFU (as per the manufacturer’s
instructions for use) in the UK healthcare system compared
with standard care for VLUs? The primary objective, based
on the outcome measures defined in the medical technologies
guidance scope (26), was to test whether there would be a dif-
ference in the change in wound area of chronic venous leg
ulcers treated for 8weeks with NLFU plus SOC compared with
SOC alone.
Methods
Ethics
The trial protocol was approved by the South East Wales
Research Ethics Committee (12/WA/0133) and conducted in
accordance with the principles of Good Clinical Practice and in
accordance with the 1975 Declaration of Helsinki. All patients
provided written consent after receiving written information
and prior to the commencement of trial procedures (ISRCTN
24438635; NCT01671748).
Study design and patient population
This study was a UK-based, single-centre, assessor-blinded,
randomised, controlled trial designed to show superiority. No
substantial amendments were made to the trial protocol after
commencement of the study. Adults with chronic venous leg
ulcers (≥6-week and ≤5-year durations, and between 5 and
100 cm2 area at randomisation) and an ankle brachial pressure
index (ABPI) of >0⋅8 were eligible to participate.
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Figure 1 Study design ﬂow diagram. NLFU,
non-contact low-frequency ultrasound; SOC, stan-
dard of care. *Compression therapy and dressing
change (with debridement if clinically necessary) at
least once a week; wound assessments weekly.
**Ultrasound therapy, with compression and dressing
change (with debridement if clinically necessary)
three times a week; wound assessments weekly.
Exclusion criteria were as follows:
• Uncontrolled diabetes [haemoglobin A1c (HbA1c)
≥12% in the last 3months]
• Index ulcer has active infection on day of inclusion
requiring systemic antibiotic therapy
• Renal failure
• Exposed tendon, ligament, muscle or bone in the index
ulcer
• Osteomyelitis, cellulitis or gangrene in study limb
• Subjects with an amputation above transmetatarsal in
study limb
• Active malignancy affecting study limb
• Index ulcer is of arterial aetiology
• Pregnant or breast feeding women or women of child-
bearing potential not willing to use a method of highly
effective contraception for the duration of the study
• Planned vascular surgery, angioplasty or thrombolysis
procedures during study period. Or patients who are
within 6weeks of having had such a procedure
• Planned surgical procedure during study period for the
index wound
• Prior skin replacement, negative-pressure therapy and
ultrasound therapy to the study wound in the 2weeks
before screening
• Currently receiving or has received radio or chemother-
apy within 3months of randomisation
• Index woundwould require ultrasound near an electronic
implant or prosthesis
• Not capable of providing informed consent
• Currently enrolled in or has been enrolled in another
investigation device or drug trial in the last 30 days.
Patients whose wounds reduced by >40% during the first 4
weeks (run in phase where SOC only was administered) were
withdrawn and did not progress to randomisation. This run-in
phase selected for wounds which were ‘hard-to-heal’ and also
standardised the care provided to patients as they had been
recruited from a variety of settings. Standard of care for the
treatment of venous leg ulcers was compression therapy with a
low adherent dressing in contact with the wound in accordance
with the NICE pathway for treatment of a patient with a venous
leg ulcer (2012).
Study procedures and assessments
Study procedures took place in a single dedicated unit spe-
cialising in wound healing research, between August 2012
and November 2013. All enrolled patients received 4weeks of
SOC prior to random allocation (run-in phase, Figure 1). SOC
comprised clinic visits once a week in which the wound was
bathed, sharp debridement was performed if necessary, and
non-adherent dressing was applied with compression delivering
40−60mmHg at the ankle. More frequent visits were arranged
if deemed clinically necessary, for example, owing to highly
exudating wound or evidence of infection. Following random
allocation, patients either continued with SOC (as described
previously) for eight further weeks or received NLFU therapy
combined with SOC (NLFU+ SOC; Figure 1).
NLFU consisted of the application of MIST ultrasound ther-
apy (Celleration Inc.) to a clean wound bed for between 3 and
12minutes (depending on the wound area) three times a week;
a non-adherent dressing and strong compression therapy was
applied after NLFU application (three times a week).
Wounds were assessed once a week for 12weeks (4-week
run-in phase plus 8-week treatment phase) and a final visit on
week 13. Assessments comprised of a wound measurement
using a Silhouette Star (ARANZ Medical, Christchurch, New
Zealand) digital imaging device, pain scoring [visual analogue
score (VAS) from 0 to 100], and condition of wound bed and
peri-ulcer skin, digital photography, and presence of malodour.
Wound margins were traced on the imaging device by a single,
blinded assessor to obtain area measurements during the treat-
ment phase. The nature and the frequency of all adverse events
(AEs) were recorded. On the first and final visits, participants
were invited to complete a Cardiff Wound Impact Schedule
(CWIS), a validated questionnaire designed to measure the
impact of chronic wounds on patient health-related quality
of life (HRQoL) (27). The questionnaire consists of three
domains: (i) physical symptoms and daily living; (ii) social
life; (iii) well-being, (transformed to a score of between 0
and 100 for each domain). The patient also provides a global
HRQoL score and satisfaction with HRQoL (each scored
between 0 and 10).
All researchers providing treatment with SOC or
NLFU+SOC, and those assessing the wound were expe-
rienced wound healing clinicians and trained appropriately to
use the NLFU device before the study started. Only patients
whose index wounds were healed by the final study visit were
interviewed by telephone 90 days later to determine whether
their index wound remained healed.
Outcome measures
The primary outcome was the change in wound area from base-
line (week 5) to week 13 (or the point of healing) controlling
for the baseline wound area measurement, as determined by
weekly digital wound measurements with blinded assessment
of wound margin. Secondary outcomes were change in HRQoL
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from enrolment to week 13 (or point of healing), incidence of
clinical infection, pain (VAS), and wound characteristics (e.g.
odour, exudate, wound bed characteristics). The proportion of
healed wounds that remained closed 90 days later was recorded.
Sample size calculation
The study was powered to detect a difference in the change in
wound area of 20% between the two arms with a two-sided
significance level and power of 90%. A standard deviation of
17⋅5% came from published literature (12). A minimum of
17 patients in each arm was required, and with an anticipated
withdrawal rate of 15%, our aim was to recruit 40 patients,
or enough participants to meet the sample size. Higher than
anticipated withdrawal rates prior to random allocation meant
that a total of 47 patients were recruited to reach the minimum
number of patients in each arm of the study as determined by
the power calculation.
Randomised allocation and assessor blinding
Following the four-week run-in phase, patients were allocated
to SOC or NLFU+ SOC using an off-site telephone service
where staff had no clinical involvement in the trial and were
not involved in the recruitment process. Patients were assigned
using a minimisation programme (MINIM) (28) to minimise
the imbalance on two prognostic factors (wound area and
wound duration) between the two arms of the trial. Both fac-
tors were unweighted and had two categories (area group 1:
≥5 and ≤10 cm2; area group 2: >10 and ≤100 cm2; duration
group 1: ≥ 6weeks and <12months; and duration group 2:
≥ 12months and ≤5 years). To reduce the possibility of selec-
tion bias, MINIM is not entirely deterministic but is approxi-
mately 70% to the preferred allocation. To further reduce the
risk of allocation prediction, the investigators were blind to the
cut-off values for each category, and the allocation was only
provided once the patient details had been irreversibly entered
into MINIM. Patients and clinicians providing care were aware
of the treatment allocation. A single primary outcome assessor
blind to treatment allocation traced the wound boundary of each
weekly wound measurement using the Silhouette Star system.
Statistical analysis
All randomised patients were included in the intention-to-treat
population. Continuous data were checked for normality using
Kolmogorov–Smirnov, z-scores for skewness and kurtosis,
visual inspection of box-plots and histograms; SOC and
NLFU+SOC data were also checked for homogeneity of
variance using the Levene’s test. Where data were normally
distributed, the mean with standard deviation (±SD) was
reported. Where data deviated from normality, medians were
reported with interquartile range (IQR).
A protocol-prescribed one-way between groups analysis
of covariance (ANCOVA) was used to analyse differences
between the NLFU+ SOC and SOC arms of the primary
endpoint, percentage change in wound area from baseline
(week 5) to final visit (week 13). Patients’ baseline (week 5)
wound area was used as the covariate. Differences between the
groups in actual change in wound area (cm2) between weeks
5 and 13 were also analysed in this way. Differences in the
primary outcome between the groups were also analysed using
a Student’s t-test and reported as non-adjusted data. ANCOVA
was also used for the secondary outcome, change in HRQoL
from weeks 1 to 13 (with week 1 HRQoL score as the covari-
ate), and a change in pain score [visual analogue scale (VAS)]
from weeks 5 to 13. All variables were checked to ensure that
the data did not violate the assumptions of normality, linearity,
homogeneity of variances and homogeneity of regression
slopes. Change in QoL scores and the number of infections
were not normally distributed, and differences between the
arms were tested using the non-parametric Mann–Whitney
U-test. Differences in the number of patients having at least one
AEwere analysed using Fisher’s exact test. In all tests, P-values
less than 0⋅05 were considered to be significant, and the tests
were two sided. No correction was applied to account for the
increased probability of a type I error associated with multiple
testing because no P-values were detected to be less than 0⋅05.
Results
Between August 2012 and August 2013, 47 patients were
enrolled into the study and 36 (77%) were randomly allocated
to receive either NLFU and standard care (NLFU+ SOC) or
standard care alone (SOC). Seventeen patients were allocated to
NLFU+SOC and 19 to SOC; no patients were withdrawn fol-
lowing random allocation on week 5. Figure 2 shows the flow of
participants through the study including reasons for withdrawal
of 11 patients during the 4-week run-in period. The main rea-
son for withdrawal prior to random allocation was reduction in
wound area of>40% in 4weeks (eight patients).Themean (SD)
age during the enrolment of the 36 patients was 69 (12) years,
the mean (SD) duration of the index ulcer at enrolment was 19
(16) months [median (range), 12⋅5 (2–54)], and the mean size
of the index ulcer was 17⋅8 cm2 (12⋅7) [median (range), 12⋅3
(6–55)]. No significant differences in the participants’ base-
line demographics were observed including ulcer characteris-
tics which are determinants of healing, for example wound size,
wound duration, and percentage healing during run-in period
(Table 1). The numbers of scheduled, additional, and missed
visits per patient are reported in Table 2. The full complement
of scheduled treatments available to patients during the 8weeks
of allocated treatment in the NLFU+SOC and SOC-only arms
was 24 and 8, respectively (excluding treatments conducted
in the final visit). Following randomisation, NLFU+ SOC and
SOC-only patients received a median (range) of 23 (20–24),
and 8 (7–8) scheduled treatments during the study, respectively
(Table 1). Each application of NLFU had a mean (SD) duration
of 3⋅8 (1⋅0) minutes. Additional visits were available to stan-
dard care patients if deemed clinically necessary by the treating
clinician. SOC patients received a median of seven additional
visits (range, 0–8) during the 8weeks of allocated treatment.
Primary outcome (change in wound area)
No statistically significant difference was observed in the
percentage change in wound area between the two arms
while controlling for the baseline wound area (measured at
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Figure 2 Participant ﬂow diagram. NLFU, non-contact low-frequency ultrasound; SAE, serious adverse event; SOC, standard of care.
randomisation at week 5; Figure 3, Table 3). Patients treated
with NLFU+SOC for 8weeks showed a −46⋅6% (SD 38⋅1%)
mean change in wound area, while patients treated with SOC
only for 8weeks showed a −39⋅2% (38⋅0%) mean change. The
difference between treatment arms [while controlling for the
effect of baseline wound area measured at week 5 which was
not significant (P= 0⋅290)] was not significant [−7⋅42% differ-
ence; 95% confidence intervals (CIs) −33⋅4–18⋅6; P= 0⋅565]
(Figure 3, Table 3). These percentage changes corresponded
to a small and non-significant difference in the actual wound
reduction between the NLFU [−6⋅18 cm2 (5⋅54)] and SOC
arms [−5⋅25 cm2 (5⋅53) of −0⋅94 cm2 (95% CIs −4⋅72 to 2⋅84;
P= 0⋅618)] (Figure 4, Table 3). In this case, the influence of the
covariate (baseline wound area) was significant (P< 0⋅001).
Patients in both arms showed a considerable reduction in
the wound area during the 12weeks of the trial (including
the 4-week run in period). NLFU+ SOC wounds showed a
mean reduction of −48⋅7% (48⋅85) and a median reduction
of −60⋅32% (range, −100% to 94⋅81%) during the 12weeks.
Standard care patients showed a mean reduction of −40⋅15%
(46⋅13%) and a median reduction of 38⋅61% (range, −100% to
85⋅27%) during the 12weeks of the study.
Three patients healed during the study period (one
NLFU+SOC patient healed after 7weeks and one after
8weeks of NLFU+ SOC treatment, and one patient who
received standard care alone healed after 4weeks). All three
of these patients remained healed 90 days after the end of their
study treatment. Ninewounds in theNLFU+ SOC arm (52⋅9%)
and seven wounds in the SOC arm (36⋅8%) reached at least
50% closure after 8weeks of treatment (not significantly dif-
ferent); 12 NLFU+SOCwounds (70⋅6%) and 10 SOCwounds
(52⋅6%) reached 25% wound closure. Two patients each in
both arms did not improve during the course of the study.
Secondary outcome
Incidence of AEs and infections
A total of 60 AEs (24 in NLFU+ SOC arm and 36 in SOC
arm) were recorded as infections of the index ulcer or peri-ulcer
skin during the course of the study. No significant differ-
ence was observed in the median number of infections per
patient between the NLFU+ SOC [2 (IQR 0–3)] and SOC arms
[2 (IQR 1–3) arms] (P= 0⋅346). Eleven NLFU+ SOC patients
and 16 SOC patients experienced at least one infection during
the study; the difference was non-significant (P= 0⋅255).
A total of 59 non-serious AEs were recorded in the NLFU
group and 70 in the standard care group, with the median
number of non-serious AEs per patient being 3 (IQR, 1⋅5–5⋅5)
for NLFU and 4 (IQR, 3–4) for standard care. Of these total
AEs, 34 in the NLFU arm were related to the index ulcer or
surrounding skin, and 59 in the standard care arm. No AEs
were related to the NLFU study device (any of ‘possibly’,
‘probably’, or ‘definitely’), and three were classified as related
to standard care treatment. One serious adverse event (SAE)
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Table 1 Baseline demographics of 36 participants allocated to receive
either NLFU+SOC or SOC alone
Baseline demographics NLFU+SOC (n=17) SOC (n=19)
Male (%)/female (%) 47/53 37/63
Age (years)
Mean (SD) 70⋅5 (12⋅7) 68⋅2 (12⋅2)
Median (range) 74⋅0 (50–91) 72⋅0 (42–86)
Weight (kg)
Mean (SD) 90⋅1 (25⋅0) 96⋅6 (20⋅1)
Median (range) 85⋅75 (67⋅8–157⋅1) 94⋅0 (55⋅1–142⋅0)
History of leg ulceration (months)
Mean (SD) 109⋅7 (112⋅2) 94⋅7 (83⋅2)
Median (range) 84⋅0 (9–468) 72⋅0 (8–300)
Index ulcer duration (months)
Mean (SD) 15⋅7 (12⋅0) 22⋅3 (18⋅5)
Median (range) 12⋅0 (2⋅0–40⋅0) 13⋅0 (1⋅5–54⋅0)
ABPI
Mean (SD) 1⋅27 (0⋅23) 1⋅23 (0⋅17)
Median (range) 1⋅25 (0⋅93–1⋅83) 1⋅21 (0⋅89–1⋅54)
Wound size at enrolment (cm2)
Mean (SD) 15⋅9 (9⋅9) 19⋅4 (14⋅90)
Median (range) 11⋅7 (5⋅9–35⋅9) 12⋅9 (6⋅5–55⋅1)
Index ulcer is recurrent (%) 13 (76⋅5) 14 (78⋅9)
Index ulcer location (%)
Malleolus 9 (52⋅9) 7 (36⋅8)
Gaiter 7 (41⋅2) 12 (63⋅2)
Calf 1 (5⋅9) 0 (0⋅0)
Change in wound size during run-in (weeks 1–5)
Mean percentage (%; SD) −10⋅9 (23⋅9) −13⋅0 (25⋅2)
Actual change (cm2; SD) −2⋅51 (4⋅2) −2⋅55 (4⋅9)
ABPI, ankle brachial pressure index; NLFU, non-contact low-frequency
ultrasound; SD, standard deviation; SOC, standard of care.
occurred after enrolment but prior to randomisation; it was
assessed as not related to the study treatment. Six AEs were
classified as moderate in nature (two NLFU+ SOC; four SOC).
Four protocol deviations were recorded during the course of
the study. Three were because of patients having dressing
changes outside of the study clinic on one occasion, and one
was because of a wound measurement being taken 4 days later
than scheduled.
Health-related quality of life
NLFU+SOC and SOC patients showed a modest improve-
ment in domains of ‘well-being’ and ‘physical symptoms and
daily living’ of the CWIS questionnaire between enrolment
and the study end (Table 4). In the domain of ‘Social Life’
NLFU+SOC patients reported an improvement of 3.0 (SD
19.8) while SOC patients did not [−0.5 (SD 19.8)]. Across all
domains of the questionnaire, differences between the groups
were not significant (Table 4). Patients were asked to rate their
overall HRQoL at the start and end of the study, as well as
their satisfaction with their HRQoL (both scored from 0 to
10). No statistically significant difference in the median change
in QoL scores between NLFU+SOC (median, −1; IQR, −2
to 2) and SOC (median, 0; IQR, −1 to 1) patients was found
(P= 0⋅490). No difference was found in the change in QoL sat-
isfaction between NLFU+SOC (median, 0; IQR, −2 to 1) and
SOC (median, 0; IQR, −1 to 1) (P= 0⋅452) arms.
Table 2 Treatment details for 36 randomised patients in the study
NLFU+SOC (n=17) SOC (n=19)
Number of scheduled treatments after randomisation per
patient (excluding ﬁnal visit; including healed weeks)
Median (range) 23 (20–24) 8 (7–8)
Mean (SD) 22⋅7 (1⋅2) 8⋅0 (0⋅2)
Number of additional visits per patient between enrolment and
study end (dressing and compression therapy application only)
Median (range) 4⋅0 (0–4)* 11⋅0 (0–12)
Mean (SD) 2⋅5 (1⋅8) 9⋅6 (2⋅9)
Number of missed treatments per patient
Median (range) 1⋅0 (0–4) 0⋅0 (0–1)
Mean (SD) 1⋅4 (1⋅2) 0⋅1 (0⋅2)
Average duration of NLFU application per patient (minutes)
Median (range) 3⋅3 (2⋅9–6⋅1) –
Mean (SD) 3⋅8 (1⋅0) –
NLFU, non-contact low-frequency ultrasound; SD, standard deviation;
SOC, standard of care.
*All additional visits were prior to randomisation for patients allocated to
receive NLFU.
Ulcer pain and other characteristics
At baseline (week 5), patients in the NLFU+SOC group had a
mean (SD) pain score of 26⋅8 (20⋅9) and median of 30⋅0 (range,
0–55) and the SOC group mean pain score was 20⋅7 (19⋅0) and
median 16⋅0 (range, 0–57; recorded on a VAS from 0 to 100).
At the study end (week 13), the NLFU+SOC patients had a
mean (SD) pain score of 10⋅8 (15⋅0) and median (range) 3⋅0
(0–48), while SOC patients’ mean was 16⋅9 (19⋅6) and median
9⋅0 (0–58) (Figure 5). NLFU+ SOC patients reported a mean
(SD) reduction in pain score [adjusted for the covariate of week
5 pain score which had a significant influence (P< 0⋅001)] of
−14⋅35 (14⋅85) points between weeks 5 and 13, while SOC
patients’ pain scores reduced by −5⋅27 (14⋅84). Figure 5 shows
non-adjusted pain reduction scores. The difference between
these adjusted scores was −9⋅08 (95% CIs, −19⋅23 to 1⋅06;
P= 0⋅078), that is, not significant. The number of patients with
malodorous wounds reduced following treatment with both
NLFU+SOC and SOC alone (Table 5). In addition, the number
of wounds which were heavily or moderately exuding reduced
in both groups following treatment (Table 5).
Discussion
The results of this study demonstrate that high-quality wound
care is instrumental in the outcome for patients with chronic
VLUs as demonstrated by the high withdrawal rate owing to
reduction in wound size during the run-in period and improve-
ment in both primary and secondary outcomes in both arms of
the study. There was a possible suggestion across several mea-
sures (including reduction in wound size, pain and complete
healing) that NLFU+ SOC arm was superior to SOC-alone
arm; however, none of these differences were statistically
significant. Therefore, it is not possible to conclude that NLFU
therapy three times a week with SOC accelerates healing in
chronic venous leg ulcers compared with SOC alone.
Although treatment with NLFU+SOC reduced the mean
wound area more than SOC alone, the difference was not
838 © 2015 The Authors. International Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons Ltd.
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Table 3 Primary outcome results from 36 patients randomised to receive either NLFU+SOC or SOC alone. Results are shown for percentage and
actual area reduction following 8weeks of treatment. Values which have been adjusted for the inﬂuence of the covariate (wound area at the beginning
of treatment) are shown alongside non-adjusted values
NLFU+SOC (n=17) SOC (n=19) Difference (95% CIs) P-value
Adjusted (planned)
Mean percentage change in wound area (%) −46⋅6 (SD, 38⋅1) −39⋅2 (SD, 38⋅0) −7⋅4 (−33⋅4 to 18⋅6) 0⋅565
Actual change in wound area (cm2) −6⋅2 (SD, 5⋅5) −5⋅3 (SD, 5⋅5) −0⋅9 (−4⋅7 to 2⋅9) 0⋅618
Non-adjusted
Percentage change in wound area (%) −47⋅8 (SD, 40⋅3) −38⋅2 (SD, 35⋅6) −9⋅6 (−35⋅3 to 16⋅1) 0⋅453
Actual change in wound area (cm2) −5⋅6 (SD, 6⋅6) −5⋅8 (SD, 6⋅2) 0⋅1 (−4⋅2 to 4⋅5) 0⋅954
CI, conﬁdence interval; NLFU, non-contact low frequency ultrasound; SD, standard deviation; SOC: standard of care.
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Figure 3 Mean percentage change in wound area from randomisation
(week 5) to each subsequent week in patients allocated to receive
8weeks of either NLFU and standard care or standard care alone. NLFU,
non-contact low-frequency ultrasound; SOC, standard of care. Error bars
represent ±1 standard error. Data for the two arms at the same time
points are offset for clarity.
significant using either percentage or actual change in wound
area. The difference in the primary outcome did not reach the
pre-defined clinically significant effect of 20% between the
arms (actual difference was −7⋅4%).
There was little difference in patient-reported measures
using the CWIS questionnaire between the groups, and overall
QoL showed little improvement from baseline in either arm.
Patients in both groups of the study reported a reduction in
pain, and although pain in the NLFU+ SOC arm reduced con-
siderably more than standard care arm, the difference was not
statistically significant. Fewer AEs, including wound-related
AEs and infections, were recorded in the NLFU group;
however, again the difference was non-significant.
This is the first randomised trial on NLFU conducted in the
UK and has several strengths. While the study was funded by
the device manufacturer, the design, conduct and analysis has
been entirely independent. Wound area measurements were
performed by a single blinded assessor using a Silhouette
digital wound planimetry device to reduce subjectivity and
bias. Broad inclusion criteria were set to maximise general-
isability, no patients withdrew following randomisation, no
patients were lost to follow-up, and best available standard
treatment was applied. Patient-reported pain and QoL data
were collected using a validated tool (CWIS) (27) to explore
outcomes important to patients. Excellent patient compli-
ance to the three times a week NLFU regime was shown
with few missed visits recorded. To improve homogeneity
amongst the wounds, a 4-week run-in period was used to
standardise pre-randomisation ulcer treatment and to remove
wounds which were not deemed hard-to-heal. In addition, the
use of ANCOVA enabled the influence of patients’ baseline
wound measurement of area reduction to be controlled, thus
improving the statistical power. Important prognostic factors
of wound size and duration were balanced between the arms
by a minimisation procedure (adaptive randomisation).
A key limitation of the study was the difference in treatment
frequency between the groups which could potentially bias
results in favour of NLFU. The rationale for this design was
Table 4 Change in Cardiff Wound Impact Schedule domain scores between start and end of the study having adjusted for inﬂuence of baseline
measurement taken at week 1. Each domain is transformed to a score of between 0 and 100. Differences in mean score changes between patients
treated with NLFU+SOC and those treated with SOC alone are shown
Cardiff Wound Impact Schedule domain NLFU+SOC (n=17) SOC (n= 19) Difference (95% CIs) P-value*
Well-being 8⋅3 (SD, 16⋅2) 8⋅0 (SD, 16⋅2) 0⋅4 (−10⋅6 to 11⋅4) 0⋅943
Physical symptoms and daily living 10⋅4 (SD, 10⋅7) 5⋅8 (SD, 10⋅7) 4⋅6 (−2⋅6 to 11⋅9) 0⋅204
Social life 3⋅0 (SD, 19⋅8) −0⋅5 (SD, 19⋅8) 3⋅5 (−10⋅0 to 17⋅0) 0⋅601
CI, conﬁdence interval; NLFU, non-contact low-frequency ultrasound; SD, standard deviation; SOC, standard of care.
*Inﬂuence of the covariate of baseline (week 1) measurement of each domain is signiﬁcant at P <0⋅05 across all three domains.
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Figure 4 Mean change in wound area (cm2) from randomisation
(week 5) to each subsequent week in patients allocated to receive
8weeks of either NLFU and standard care or standard care alone. NLFU,
non-contact low-frequency ultrasound; SOC, standard of care. Error bars
represent ±1 standard error. Data for the two arms at the same time
points are offset for clarity.
to compare the manufacturer’s instructions for use (three times
a week) with UK standard practice (treatment at least once a
week) (2). Of note is the high frequency with which additional
visits were applied (a median of one extra visit for each SOC
patient each week). Although the sample size of the study was
small, it was calculated to show a substantial clinical effect in
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Figure 5 Mean change in patient reported pain scores from randomi-
sation (week 5) to each subsequent week in patients allocated to
receive 8weeks of either NLFU+SOC or SOC alone. NLFU, non-contact
low-frequency ultrasound; SOC, standard of care. Pain was measured
on a visual analogue scale (VAS) from 0 to 100. Error bars represent±1
standard error.
line with the claims made by the device manufacturer. How-
ever, the standard deviation proved to be larger than estimated
from the available literature which resulted in the study having
reduced statistical power. A larger sample size may narrow
the confidence intervals and a primary outcome in favour of
NLFU may be detected (the clinically important difference of
Table 5 Wound bed characteristics including wound bed condition, level of exudate, and wound odour, of patients before enrolment, at randomisation,
and at study end. Each value refers to the number of patients in each group with percentages in parentheses
NLFU+SOC SOC
At enrolment Pre-treatment Post-treatment Pre-treatment Post-treatment
Fibrin
<50% 21 (58⋅3%) 15 (88⋅2%) 15 (88⋅2%) 12 (63⋅2%) 12 (63⋅2%)
≥50% 15 (41⋅7%) 2 (11⋅8%) 2 (11⋅8%) 7 (36⋅8%) 7 (36⋅8%)
Slough/necrosis
<50% 25 (69⋅4%) 9 (52⋅9%) 14 (82⋅4%) 18 (94⋅7%) 19 (100%)
≥50% 11 (30⋅6%) 8 (47⋅1%) 3 (17⋅6%) 1 (5⋅3%) 0 (0%)
Granulation
<50% 20 (55⋅6%) 9 (52⋅9%) 9 (52⋅9%) 9 (47⋅4%) 8 (42⋅1%)
≥50% 16 (44⋅4%) 8 (47⋅1%) 8 (47⋅1%) 10 (52⋅6%) 11 (57⋅9%)
Level of exudate
None 0 (0%) 0 (0%) 2 (11⋅8%) 0 (0%) 1 (5⋅3%)
Minimal 9 (25⋅0%) 1 (5⋅9%) 9 (52⋅9%) 5 (26⋅3%) 12 (63⋅2%)
Moderate 24 (66⋅7%) 12 (70⋅6%) 5 (29⋅4%) 12 (63⋅2%) 6 (31⋅6%)
Heavy 3 (8⋅3%) 4 (23⋅5%) 1 (5⋅9%) 2 (10⋅5%) 0 (0%)
Copious 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Wound odour
Yes 1 (2⋅8%) 4 (23⋅5%) 1 (5⋅9%) 2 (10⋅5%) 1 (5⋅3%)
No 35 (97⋅2%) 13 (76⋅5%) 16 (94⋅1) 17 (89⋅5%) 18 (94⋅7%)
NLFU, non-contact low-frequency ultrasound; SOC, standard of care.
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−20% was within the 95% CI), although the data presented
in Figures 3 and 4 do not show a marked difference in the
outcome between using NLFU+ SOC and SOC only.
The treatment period of the trial was 8weeks, and the
outcome was percentage area reduction of the wound. A
substantially longer trial would be required for the proportion
of 100% healed wounds to be used as an outcome measure
which Gottrup has argued is a better outcome measure (29).
The ability of 4-week wound reduction to predict healing is
well documented (30) and may have been a more appropriate
factor than wound area upon which to balance the trial groups.
The open-label nature of this study may also have introduced
performance bias in favour of NLFU. Blinding of patients and
clinicians can be difficult to administer and maintain in medical
device trials (31); a sham device was carefully considered but
ultimately ruled out owing to the complexity and inability to
separate any ultrasound-mediated effect from the debriding
effects of the device.
Enrolment of homogenous groups of patients in chronic
wound healing studies is notoriously difficult. The chronicity
of many of the patient’ ulcerations was further complicated by
ulcer recurrence and effects of skin changes as a result of the
underlying disease. The large standard deviation in the primary
outcome reflects the heterogeneous nature of wound healing
progression. In both arms, there were two patients whose
index ulcer grew in size following randomisation. Review of
the patients’ cases revealed that the worsening NLFU+ SOC
patients were because of (i) merging the large index ulcer
(18⋅7 cm2) with a small satellite ulcer (1 cm2), and (ii) possible
underlying infection which recurred during the study. Addi-
tional analysis showed that removal of each patient did not
result in a change to the statistical significance of the results.
The results of this study are reflective of results seen in many
other wound studies. Where the primary end point is healing,
the results often show little or no compelling evidence of a sig-
nificant difference between the arms. It is possible that NLFU
had a positive influence on the trajectory of wound healing
and that identification of factors indicative of ‘responders’ ver-
sus ‘non-responders’ may be of value. Clinicians currently rely
on subjective wound assessments that may not identify subtle
changes within the wound.
Practitioner feedback was that NLFU treatment was well
tolerated by patients, it did not add to the patient’s pain or
discomfort, and for some patients, there was a decrease in
pain following treatment (although the difference between arms
of the trial was not significant). NLFU was very easy to use
within the clinical setting. Following the completion of the
study and during return clinic visits by the patients at various
time points, practitioners have noted that a further 9 patients in
the NLFU+ SOC arm (from a total of 17) and 5 patients in the
SOC only arm (from a total of 19) went on to complete healing.
While this observation should be interpreted cautiously because
it was not a study outcome, it suggests that a study with a longer
follow-up, and including patients that have not healed at the end
of the study, may identify benefits related to NLFU which were
not captured in this study.
This study suggests that while patients receiving
NLFU+SOC showed a substantial improvement in their
wounds, most, if not all of this effect was because of
high-quality SOC (compression therapy with appropriate
dressings) applied by highly skilled practitioners in the context
of a clinical trial unit. Early identification of local and sys-
temic infection improved patient outcomes. Furthermore, this
randomised controlled trial demonstrates the limited value of
single-arm baseline-controlled studies where the influence of
the compression therapy and best practice in the trial context
is obscured. Reporting of such studies leads to inflated effect
sizes such as those in the meta-analysis carried out by Driver
et al. (32), which estimated a wound area reduction of 85⋅2%
in approximately 7weeks owing to NLFU therapy.
Three other randomised controlled trials and a small pilot
RCT have been conducted to evaluate the use of NLFU as a
treatment for chronic lower limb wounds (10,16–18). A large
volume of non-comparative or baseline-controlled retrospec-
tive and prospective studies also exist which report that NLFU
enhances healing of chronic wounds. A small study such as this
has wide CIs; it is possible that a much larger trial would show a
statistically significant effect, although the effect size might still
be small. This study was designed to be pragmatic and gener-
alisable, as such the possibility remains that a narrower pop-
ulation with more recalcitrant wounds may respond to NLFU.
Excluding patients whosewounds reduce by>30% in the run-in
phase may be an appropriate way to do this. In addition, the
results of this study do not preclude NLFU as a treatment option
for wounds other than venous leg ulcers, and the results of other
NLFU regimes and doses cannot be extrapolated.
This is the first clinical trial to be conducted in response to
questions raised in Medical Technologies Guidance issued by
the NICE, the aim being to produce published results to address
the uncertainties in the evidence base in a short time period and
independently of both NICE and the device manufacturer.
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